cisplatin + gemcitabine + interferon alfa

Cisplatin + gemcitabine + interferon alfa is an investigational combination thermochemotherapy regimen developed by The University of Texas Health Science Center, Houston (UTHealth), under the leadership of Dr. Joan M.C. Bull. This multi-agent protocol is specifically designed to be administered in conjunction with fever-range whole-body thermal therapy (FR-WB-TT), which involves elevating the patient's core body temperature to approximately 40°C (104°F). The regimen consists of three active components: cisplatin, a platinum-based chemotherapy agent that crosslinks DNA to inhibit tumor cell division; gemcitabine, a nucleoside analog that disrupts DNA synthesis; and low-dose metronomic interferon alfa, a biologic agent that provides immunomodulatory and anti-angiogenic effects. This combination targets DNA replication machinery and tumor vasculature, leveraging the sensitizing effects of hyperthermia to enhance cancer cell kill. It has been evaluated in Phase I/II clinical trials for advanced solid tumors, including small-cell lung cancer, neuroendocrine cancer, and gastric cancer.

Brand names

Gemzar

Other names

Cisplatin + Gemcitabine + IFN-aCisplatin + Gemcitabine + Interferon-alphaCisplatin + Gemcitabine HCl + Low-Dose Metronomic Interferon-a